KETAMINE INJECTION, VETERINARY

Ketamine Hydrochloride Injection, USP, in 10 mL multiple-dose vials, is a DEA Schedule C-III controlled substance classified for veterinary use, subject to strict handling and storage requirements including storage in a vault at medically controlled room temperature. The item is regulated by the FDA and must comply with Medical Marking Standard No. 1, superseding MIL-STD-129, with all packaging and labeling aligned to DLA’s Packaging Requirements for Procurement RP001. The product carries a non-extendable 24-month shelf life under RS016 requirements, and each unit must be sealed in commercial-grade containers capable of preventing damage, with palletization and exterior packaging conforming to DLA standards for safe transport via common carrier. Deliveries are required FOB destination within 89 days of contract award, with no tolerance for quantity variance, and must be shipped to the specified military medical logistics hub in Kaiserslautern, Germany, or to APO AE 09227-0000, with inspection and acceptance occurring at the delivery point. The contract, identified by solicitation number SPE2DP-26-T-4257 and NSN 6509-01-712-2920, is issued by the Department of Defense under the Medical Supply Chain Pharm FSA, requiring precise adherence to federal procurement and pharmaceutical handling protocols. The item is procured in a single unit of issue, with a required delivery date of July 23, 2026, and response deadline of July 29, 2026. Only approved vendors—Patterson Veterinary Supply, Inc., Covetrus North America, LLC, and Zoetis Inc.—with authorized part numbers may submit bids. All submissions must include manufacturer details and product specifications for FDA referral via EBS, and the item is subject to Covered Defense Information protocols under RD003. Commercial packaging is mandated, with no government identification to be removed from non-accepted supplies per RQ011, and all markings must conform to the latest Medical Marking Standard No. 1 as published by DLA Troop Support.